Evidence map›Paper›PMID 41702899›Full record

ArticleNature communications2026

Nanobody-based IgG simultaneously inhibit the allergenic and enzymatic activity of the dominant honeybee venom allergen.

Josephine Baunvig Aagaard, Rosaria Gandini, Anne-Sofie Ravn Ballegaard, Bjarke Krogstrup Jensen, Britta Dorn, Amanda Verner Borg Larsen, Anders Lenstrup, Mathias Sønderholm, Michaela Miehe, Wolfgang Pfützner and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Josephine Baunvig AagaardDepartment of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.
Rosaria GandiniDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Anne-Sofie Ravn BallegaardDepartment of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.
Bjarke Krogstrup JensenDepartment of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.ORCID http://orcid.org/0009-0009-0583-2459
Britta DornDepartment of Dermatology and Allergology, Justus Liebig University Giessen, Giessen, Germany.
Amanda Verner Borg LarsenDepartment of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.
Anders LenstrupDepartment of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.
Mathias SønderholmDepartment of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.
Michaela MieheDepartment of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.
Wolfgang PfütznerDepartment of Dermatology and Allergology, Clinical & Experimental Allergology, Philipps University Marburg, Marburg, Germany.ORCID http://orcid.org/0000-0002-8721-724X
Thilo JakobDepartment of Dermatology and Allergology, Justus Liebig University Giessen, Giessen, Germany. thilo.jakob@derma.med.uni-giessen.de.ORCID http://orcid.org/0000-0002-3124-9998
Gregers Rom AndersenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark. gra@mbg.au.dk.ORCID http://orcid.org/0000-0001-6292-3319
Christian MöbsDepartment of Dermatology and Allergology, Clinical & Experimental Allergology, Philipps University Marburg, Marburg, Germany. moebs@med.uni-marburg.de.ORCID http://orcid.org/0000-0002-5197-7669
Edzard SpillnerDepartment of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark. e.spillner@bce.au.dk.ORCID http://orcid.org/0000-0003-0999-5254

Funding

Det Frie Forskningsråd (Danish Council for Independent Research) 0135-00061BDet Frie Forskningsråd (Danish Council for Independent Research) 9041-00291ANovo Nordisk Fonden (Novo Nordisk Foundation) NNF19OC0058484Von-Behring-Röntgen-Stiftung (Von Behring-Röntgen-Foundation) 66-0004
6 · The paper itself

Abstract

Insect venoms can cause severe allergic reactions, including anaphylaxis, in sensitized individuals. In this study, we aim at preventing anaphylaxis mediated by the most abundant and dominant honeybee venom allergen phospholipase A2 (Api m 1) by blocking its interaction with allergic patient IgE. Therefore, we characterize selected Api m 1-specific nanobodies and identify two high-affinity binders with non-overlapping epitopes. Crystal structures of Api m 1/nanobody complexes reveal diametrically opposed epitopes, one of which involves the active site of Api m 1. Based on this background, we develop mono- and bispecific nanobody-human IgG

Indexed as

AllergensBee VenomsImmunoglobulin GInsect ProteinsSingle-Domain AntibodiesVenom HypersensitivityAnaphylaxisAnimalsBeesEpitopesFemaleHumansImmunoglobulin EMicePhospholipases APhospholipases A2AllergensApi m 1 allergen, Apis melliferaBee VenomsEpitopesImmunoglobulin EImmunoglobulin GInsect ProteinsPhospholipases APhospholipases A2Single-Domain Antibodies

Identifiers

PMID41702899
PMCPMC12917253

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.